59717-96-3

Basic information

• Product Name: 5-bromo-2-phenoxypyridine
• Synonyms: 5-bromo-2-phenoxypyridine;Pyridine,5-bromo-2-phenoxy-
• CAS NO: 59717-96-3
• Molecular Formula: C₁₁H₈BrNO
• Molecular Weight: 250.094
• Mol File: 59717-96-3.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 310.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.476±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.18±0.22(Predicted)
• CAS DataBase Reference: 5-bromo-2-phenoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-phenoxypyridine(59717-96-3)
• EPA Substance Registry System: 5-bromo-2-phenoxypyridine(59717-96-3)

Safety Data

• Hazardous Substances Data: 59717-96-3(Hazardous Substances Data)

Usage

General Description

5-bromo-2-phenoxypyridine is a chemical compound with a molecular formula C11H7BrNO. It is a heterocyclic aromatic compound that contains a pyridine ring with a bromine atom at the 5-position and a phenoxide group at the 2-position. 5-bromo-2-phenoxypyridine is commonly used as a building block in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. It has also been studied for its potential applications in materials science and as a ligand in coordination chemistry. 5-bromo-2-phenoxypyridine is considered to be a versatile and valuable intermediate in the synthesis of complex organic compounds.

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 108-95-2 phenol 
• 766-11-0 5-bromo-2-fluoropyridine 

Downstream Products

• 595576-33-3 5-butyl-2-phenoxypyridine 
• 595576-32-2 2-phenoxy-5-propylpyridine 
• 595576-28-6 3-(6-phenoxypyridin-3-yl)acrylic acid methyl ester 
• 330792-76-2 2-phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine 
• 173282-69-4 3-formyl-6-phenyloxypyridine 
• 1201645-39-7 2-(4-((3-nitro-6-(6-phenoxypyridin-3-yl)quinolin-4-yl)methyl)phenyl)-2-methylpropanenitrile 
• 1270921-80-6 (6-phenoxypyridin-3-yl)boronic acid 

Relevant articles and documents

Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma

Ibrutinib (IBN), a first-in-class BTK-inhibitor, was approved by the FDA for the treatment of mantle cell lymphoma (MCL). Although IBN shows excellent performance as an anti-lymphoma agent, it has some undesirable side effects due to its off-target activities. Our studies yielded a novel series of 3-(6-phenoxypyridin-3-yl)-4-amine-1H-pyrazolo[3,4-d]pyrimidine derivatives capable of potent inhibition of Bruton's tyrosine kinase (BTK). Notably, compound 13e explained potent BTK inhibitory activity and could completely inhibit the phosphorylation of BTK and PLCγ2 in Z138 cells at low micromolar concentration. Compared with IBN, compound 13e improved anti-proliferative activities 3–40 folds in MCL cell lines with IC50 values lower than 1 μM. Low micromolar doses of 13e could induce strong cell apoptosis in Jeko-1 and Z138 cells. In addition, compound 13e showed greater BTK selectivity and higher stability in human liver microsomes than IBN and potential safety improvement for the treatment of MCL.

1, 3-di-substituted-4-amino pyrazolopyrimidine compound, preparation method thereof and application of compound

The invention relates to a 1, 3-di-substituted-4-amino pyrazolopyrimidine compound, a preparation method thereof and an application of the compound. The compound is provided with a structure as shownin a formula I. The invention further relates to a preparation method of the compound with the structure as shown in the formula I and a medicine composition. The invention further provides an application of the compound and pharmaceutically acceptable salt thereof to preparation of MCL (mantle cell lymphoma) resistance medicines.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.